

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

One ml contains:

### **Active substance:**

Meloxicam 20 mg

### **Excipient:**

Ethanol 150 mg

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Solution for injection.

Clear yellow solution.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Cattle, pigs and horses.

### **4.2 Indications for use, specifying the target species**

#### Cattle

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

#### Pigs

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxæmia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

#### Horses

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.

For the relief of pain associated with equine colic.

### **4.3 Contraindications**

See also section 4.7.

Do not use in horses less than 6 weeks of age.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.  
For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

#### **4.4 Special warnings for each target species**

Treatment of calves with Emdocam 20 minutes before dehorning reduces post-operative pain. Emdocam alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery, co-medication with an appropriate analgesic is needed.

#### **4.5 Special precautions for use**

##### **Special precautions for use in animals**

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

##### **Special precautions to be taken by the person administering the veterinary medicinal product to animals**

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.

In horses, a transient swelling at the injection site can occur but resolves without intervention.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals, including isolated reports treated).

#### **4.7 Use during pregnancy, lactation or lay**

**Cattle and pigs:** Can be used during pregnancy and lactation.

**Horses:** Do not use in pregnant or lactating mares.

#### 4.8 Interaction with other medicinal products and other forms of interaction

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant medicinal products.

#### 4.9 Amounts to be administered and administration route

##### Cattle

Single subcutaneous or intravenous injection at a dose of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

##### Pigs

Single intramuscular injection at a dose of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

##### Horses

Single intravenous injection at a dose of 0.6 mg meloxicam/kg body weight (i.e. 3 ml/100 kg body weight).

For use in the alleviation of inflammation and the relief of pain in both acute and chronic musculo – skeletal disorders, a suitable oral therapy containing meloxicam, administered in accordance with label recommendations, may be used for continuation of treatment.

Avoid introduction of contamination during use.

Do not breach the vial more than 50 times.

#### 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

In case of overdose, symptomatic treatment should be initiated.

#### 4.11 Withdrawal periods

**Cattle:** Meat and offal: 15 days; Milk: 5 days

**Pigs:** Meat and offal: 5 days

**Horses:** Meat and offal: 5 days.

Not authorised to use in horses producing milk for human consumption.

### 5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams)

ATCvet code: QM01AC06

#### 5.1 Pharmacodynamic properties

Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B<sub>2</sub> induced by *E. coli* endotoxin administration in calves, lactating cows and pigs.

## 5.2 Pharmacokinetic particulars

### Absorption

After a single subcutaneous dose of 0.5 mg meloxicam/kg,  $C_{\max}$  values of 2.1 µg/ml and 2.7 µg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.

After two intramuscular doses of 0.4 mg meloxicam/kg, a  $C_{\max}$  value of 1.9 µg/ml was reached after 1 hour in pigs.

### Distribution

More than 98 % of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

### Metabolism

Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. The metabolism in horses has not been investigated.

### Elimination

Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively.

In pigs, after intramuscular administration the mean plasma elimination half-life is approximately 2.5 hours.

In horses, after intravenous injection meloxicam is eliminated with a terminal half-life of 8.5 hours.

Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

- Ethanol (96%)
- Poloxamer 188
- Macrogol 300
- Glycine
- Sodium hydroxide
- Hydrochloric acid
- Meglumine
- Water for injections

### 6.2 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### 6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years

Shelf-life after first opening the immediate packaging: 28 days

#### **6.4 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

#### **6.5 Nature and composition of immediate packaging**

Pack size of 1 colourless Type I glass vial containing 50 ml, 100 ml or 250 ml. Each vial is closed with a bromobutyl rubber stopper and sealed with an aluminium cap.  
Not all pack sizes may be marketed.

#### **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

### **7. MARKETING AUTHORISATION HOLDER**

Emdoka bvba  
J. Lijzenstraat 16  
B-2321 Hoogstraten  
Belgium

### **8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/128/001-003

### **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 18.08.2011  
Date of last renewal: 21.06.2016

### **10. DATE OF REVISION OF THE TEXT**

DD.MM.YYYY

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

### **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 15 mg/ml oral suspension for horses

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

### **Active substance:**

Meloxicam 15.0 mg

### **Excipients:**

Sodium benzoate 1.5 mg

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Oral suspension

Yellow suspension.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Horses

### **4.2 Indications for use, specifying the target species**

Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.

### **4.3 Contraindications**

Do not use in pregnant or lactating mares.

Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in horses less than 6 weeks of age.

### **4.4 Special warnings for each target species**

None.

### **4.5 Special precautions for use**

#### Special precautions for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of renal toxicity.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

#### **4.6 Adverse reactions (frequency and seriousness)**

Isolated cases of adverse reactions typically associated with NSAIDs were observed in clinical trials (slight urticaria, diarrhoea). Symptoms were reversible.

Loss of appetite, lethargy, abdominal pain and colitis have been reported in very rare cases.

Anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically in very rare cases.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

Laboratory studies in cattle have not provided any evidence for teratogenic, foetotoxic, or maternotoxic effects. However, no data have been generated in horses. Therefore the use in this species is not recommended during pregnancy and lactation.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticoids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.

#### **4.9 Amounts to be administered and administration route**

To be administered either mixed with food or directly into the mouth at a dosage of 0.6 mg/kg body weight, once daily, up to 14 days. In case the product is mixed with food, it should be added to a small quantity of food, prior to feeding.

The suspension should be given using the measuring syringe provided in the package. The syringe fits onto the bottle and has volume scale and a “kg-body weight” scale which corresponds to the maintenance dose (i.e. 0.6 mg meloxicam / kg body weight).

Shake well before use.

After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

Avoid introduction of contamination during use.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**



In case of overdose symptomatic treatment should be initiated.

#### **4.11 Withdrawal period(s)**

Meat and offal: 3 days.

Not authorised for use in horses producing milk for human consumption.

### **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids (oxicams).  
ATCvet code: QM01AC06.

#### **5.1 Pharmacodynamic properties**

Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B<sub>2</sub> induced by intravenous *E. coli* endotoxin administration in calves and pigs.

#### **5.2 Pharmacokinetic particulars**

##### Absorption

When the product is used according to the recommended dosage regime the oral bioavailability is approximately 98 %. Maximal plasma concentrations are obtained after approximately 2–3 hours. The accumulation factor of 1.08 suggests that meloxicam does not accumulate when administered daily.

##### Distribution

Approximately 98 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.12 l/kg.

##### Metabolism

The metabolism is qualitatively similar in rats, mini-pigs, humans, cattle and pigs although quantitatively there are differences. The major metabolites found in all species were the 5-hydroxy- and 5-carboxy-metabolites and the oxalyl-metabolite. The metabolism in horses was not investigated. All major metabolites have been shown to be pharmacologically inactive.

##### Elimination

Meloxicam is eliminated with a terminal half-life of 7.7 hours.

### **6. PHARMACEUTICAL PARTICULARS**

#### **6.1 List of excipients**

Sodium benzoate

Sorbitol, liquid

Glycerol

Saccharin sodium

Xylitol

Sodium dihydrogen phosphate dihydrate

Silica, colloidal anhydrous

Xanthan gum

Citric acid  
Honey aroma  
Purified water

## **6.2 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## **6.3 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf-life after first opening of the immediate packaging: 6 months.

## **6.4 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

## **6.5 Nature and composition of immediate packaging**

High density polyethylene bottle with a HDPE tamper-proof child-resistant screw cap and a 24 ml polypropylene measuring syringe with a volume scale and a “kg-body weight” scale which corresponds to the maintenance dose (i.e. 0.6 mg meloxicam / kg body weight).

### Pack sizes:

Cardboard box with 1 bottle of 125 ml and a measuring syringe

Cardboard box with 1 bottle of 336 ml and a measuring syringe

Not all pack sizes may be marketed.

## **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Emdoka bvba  
J. Lijzenstraat 16  
B-2321 Hoogstraten  
Belgium

## **8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/128/009 (125 ml)

EU/2/11/128/010(336 ml)

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 18.08.2011

Date of last renewal: 21.06.2016

#### **10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

#### **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 5 mg/ml solution for injection for cattle and pigs

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

### **Active substance:**

Meloxicam 5 mg

### **Excipients:**

Ethanol 150 mg

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Solution for injection.

Clear yellow solution.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Cattle (calves and young cattle) and pigs

### **4.2 Indications for use, specifying the target species**

#### **Cattle:**

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For the relief of post-operative pain following dehorning in calves.

#### **Pigs:**

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For the relief of post-operative pain associated with minor soft tissue surgery such as castration.

### **4.3 Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

#### **Cattle:**

Do not use in cattle suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

#### **Pigs:**

Do not use in pigs suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in pigs less than 2 days old.

#### 4.4 Special warnings for each target species

##### **Cattle:**

Treatment of calves with Emdocam 20 minutes before dehorning reduces post-operative pain.

Emdocam alone will not provide adequate pain relief during the dehorning procedure.

To obtain pain relief during surgery co-medication with an appropriate anaesthetic/sedative/analgesic is needed.

To obtain the best possible pain-relieving effect post-surgery Emdocam should be administered 30 minutes before surgical intervention.

##### **Pigs:**

Treatment of piglets with Emdocam before castration reduces post-operative pain.

To obtain pain relief during surgery co-medication with an appropriate anaesthetic/sedative/analgesic is needed.

To obtain the best possible pain-relieving effect post-surgery Emdocam should be administered 30 minutes before surgical intervention.

#### 4.5 Special precautions for use

##### Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

During anaesthesia, monitoring and fluid therapy should be considered as standard practice.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Meloxicam may cause allergic reactions. People with known hypersensitivity to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

Accidental self-injection may give rise to pain. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

#### 4.6 Adverse reactions (frequency and seriousness)

Subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.

Anaphylactic reactions, which may be serious (including fatal), may occur in very rare cases and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

**Cattle:** Can be used during pregnancy.

**Pigs:** Can be used during pregnancy and lactation.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.

#### **4.9 Amounts to be administered and administration route**

Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of body weight.

Avoid introduction of contamination during use.

**Cattle:**

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

**Pigs:**

Locomotor disorders:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/25 kg body weight). If required, a second administration of meloxicam can be given after 24 hours.

Reduction of post-operative pain:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 0.4 ml/5 kg body weight) before surgery.

As the vial should not be breached more than 50 times the user should select the most appropriate vial size according to the target species to be treated.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In case of overdose symptomatic treatment should be initiated.

#### **4.11 Withdrawal periods**

**Cattle** (calves and young cattle): Meat and offal: 15 days

**Pigs:** Meat and offal: 5 days

### **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams) ATCvet code: QM01AC06

#### **5.1 Pharmacodynamic properties**

Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and

antipyretic properties. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. *In vitro* and *in vivo* studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1). Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B<sub>2</sub> induced by *E. coli* endotoxin administration in calves and pigs.

## **5.2 Pharmacokinetic particulars**

### Absorption

After a single subcutaneous dose of 0.5 mg meloxicam/kg, C<sub>max</sub> values of 2.1 µg/ml were reached after 7.7 hours in young cattle.

Following single intramuscular doses of 0.4 mg meloxicam/kg, a C<sub>max</sub> value of 1.1 to 1.5 µg/ml was reached within 1 hour in pigs.

### Distribution

More than 98 % of meloxicam is bound to plasma proteins in cattle and pigs.

In cattle and pigs, the highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

### Metabolism

Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolized to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

The main pathway of meloxicam biotransformation is oxidation.

### Elimination

Meloxicam is eliminated with a half-life of 26 hours after subcutaneous injection in young cattle. In pigs, after intramuscular administration, the mean plasma elimination half-life is approximately 2.5 hours. Approximately 50% of the administered dose is eliminated via urine and the remainder via faeces.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Ethanol  
Poloxamer 188  
Sodium chloride  
Glycine  
Hydrochloric acid  
Sodium hydroxide  
Glycofurol  
Meglumine  
Water for injections

### **6.2 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **6.3 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf-life after first opening the immediate packaging: 28 days

### **6.4. Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **6.5 Nature and composition of immediate packaging**

Colourless type I glass vials closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

#### Pack sizes:

Cardboard box containing 1 vial of 50 ml

Cardboard box containing 1 vial of 100 ml

Cardboard box containing 1 vial of 250 ml

Not all pack sizes may be marketed.

### **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Emdoka bvba  
John Lijsenstraat 16  
2321 Hoogstraten  
Belgium

## **8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/128/004-006

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 18.08.2011

Date of last renewal: 21.06.2016

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

## **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.



## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 5 mg/ml solution for injection for dogs and cats

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each ml contains:

### **Active substance:**

Meloxicam 5 mg

### **Excipients:**

Ethanol 150 mg

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Solution for injection.

Clear yellow solution.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Dogs, cats

### **4.2 Indications for use, specifying the target species**

#### **Dogs:**

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

#### **Cats:**

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

### **4.3 Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in pregnant or lactating dogs and cats.

Do not use in dogs and cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in dogs and cats less than 6 weeks of age nor in cats of less than 2 kg.

### **4.4 Special warnings for each target species**

None.

## **4.5 Special precautions for use**

### Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

During anaesthesia, monitoring and fluid therapy should be considered as standard practice.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Meloxicam may cause allergic reactions. People with known hypersensitivity to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

Accidental self-injection may give rise to pain. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

## **4.6 Adverse reactions (frequency and seriousness)**

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have rarely been reported.

Elevated liver enzymes have been reported in very rare cases.

Haemorrhagic diarrhoea, haematemesis and gastrointestinal ulceration have been reported in very rare cases. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

Anaphylactoid reactions may occur and should be treated symptomatically in very rare cases.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

## **4.7 Use during pregnancy, lactation or lay**

The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3).

## **4.8 Interaction with other medicinal products and other forms of interaction**

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Emdocam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic veterinary medicinal products should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

#### 4.9 Amounts to be administered and administration route

Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of body weight.

Avoid introduction of contamination during use.

##### **Dogs:**

###### Musculo-skeletal disorders:

Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight).

###### Reduction of post-operative pain (over a period of 24 hours):

Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight) before surgery, for example at the time of induction of anaesthesia.

##### **Cats:**

###### Reduction of post-operative pain:

Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia.

As the vial should not be breached more than 50 times the user should select the most appropriate vial size according to the target species to be treated.

#### 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

In case of overdose symptomatic treatment should be initiated.

#### 4.11 Withdrawal periods

Not applicable.

### 5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams) ATCvet code: QM01AC06

#### 5.1 Pharmacodynamic properties

Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic properties. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. *In vitro* and *in vivo* studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

#### 5.2 Pharmacokinetic particulars

##### Absorption

Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 µg/ml in dogs and 1.1 µg/ml in cats were reached approximately 2.5 hours and 1.5 hours post administration, respectively.

### Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range in dogs and cats. more than 97% of meloxicam is bound to plasma proteins in dogs and cats.

The volume of distribution is 0.3 l/kg in dogs and 0.09 l/kg in cats.

### Metabolism

Meloxicam is predominantly found in plasma. It is also a major biliary excretion product in dogs and cats whereas urine contains only traces of the parent compound

In cats five major metabolites were detected all having been shown to be pharmacologically inactive.

The main pathway of meloxicam biotransformation is oxidation.

### Elimination

In dogs and cats, Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine in dogs.

In cats, the detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion. 21 % of the recovered dose is eliminated in urine (2 % as unchanged meloxicam, 19 % as metabolites) and 79 % in the faeces (49 % as unchanged meloxicam, 30 % as metabolites).

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Ethanol  
Poloxamer 188  
Sodium chloride  
Glycine  
Hydrochloric acid  
Sodium hydroxide  
Glycofurol  
Meglumine  
Water for injections

### **6.2 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **6.3 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 3years.

Shelf-life after first opening the immediate packaging: 28 days

### **6.4. Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **6.5 Nature and composition of immediate packaging**

Colourless type I glass vials closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

Pack sizes:

Cardboard box containing 1 vial of 20 ml

Cardboard box containing 1 vial of 50 ml

Not all pack sizes may be marketed.

**6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Emdoka bvba  
John Lijzenstraat 16  
2321 Hoogstraten  
Belgium

**8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/128/007-008

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 18.08.2011

Date of last renewal: 21.06.2016

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

**PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## **ANNEX II**

- A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE**
- C. STATEMENT OF THE MRLs**

#### A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Produlab Pharma bv  
NL-4941 SJ Raamsdonksveer  
The Netherlands

#### B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE

Veterinary medicinal product subject to prescription.

#### C. STATEMENT OF THE MRLs

Meloxicam in Emdocam 20 mg/ml solution for injection for cattle, pigs and horses is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:

Pharmacologically active substance	Marker residue	Animal species	MRL	Target tissues	Other provisions	Therapeutic classification
Meloxicam	Meloxicam	Bovine, caprine, porcine, rabbit, <i>Equidae</i>	20 µg/kg 65 µg/kg 65 µg/kg	Muscle Liver Kidney	No entry	Anti-inflammatory agents/Non-steroidal anti-inflammatory agents
		Bovine, caprine	15 µg/kg	Milk		

The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**



## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**OUTER CARTON - 50, 100 or 250 ml vials**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 20 mg/ml solution for injection for cattle, pigs and horses  
meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 20 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE(S)**

50 ml  
100 ml  
250 ml

**5. TARGET SPECIES**

Cattle, pigs and horses

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

**Cattle:** S.C., I.V.  
**Pigs:** I.M.  
**Horses:** I.V.

Read the package leaflet before use.

**8. WITHDRAWAL PERIODS**

Withdrawal periods:

**Cattle:** meat and offal: 15 days; milk: 5 days.  
**Pigs:** meat and offal: 5 days.  
**Horses:** meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Shelf-life after first opening of the container: 28 days.

Once broached, use by \_\_\_\_\_

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS , IF ANY**

Disposal: read package leaflet.

**13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS "KEEP OUT OF SIGHT AND REACH OF CHILDREN"**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Emdoka bvba  
J. Lijssenstraat 16  
B-2321 Hoogstraten  
Belgium

**16. MARKETING AUTHORISATION NUMBERS**

EU/2/11/128/001

EU/2/11/128/002

EU/2/11/128/003

**17. MANUFACTURER'S BATCH NUMBER**

Batch

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE****Vial label for 100 ml and 250 ml****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 20 mg/ml solution for injection for cattle, pigs and horses  
meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 20 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE(S)**

100 ml  
250 ml

**5. TARGET SPECIES**

Cattle, pigs and horses

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

**Cattle:** SC, IV  
**Pigs:** IM  
**Horses:** IV

Read the package leaflet before use.

**8. WITHDRAWAL PERIODS**

Withdrawal periods:

**Cattle:** meat and offal: 15 days; milk: 5 days.

**Pigs:** meat and offal: 5 days.

**Horses:** meat and offal: 5 days.

Not authorised to use in horses producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Shelf-life after first opening the container: 28 days.

Once broached, use by...

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS , IF ANY**

Read the package leaflet before use.

**13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Emdoka bvba  
J. Lijsenstraat 16  
B-2321 Hoogstraten  
Belgium

**16. MARKETING AUTHORISATION NUMBERS**

EU/2/11/128/002

EU/2/11/128/003

**17. MANUFACTURER'S BATCH NUMBER**

Batch

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS****Vial label for 50 ml****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 20 mg/ml solution for injection for cattle, pigs and horses  
meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 20 mg/ml

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

50 ml

**4. ROUTE(S) OF ADMINISTRATION**

**Cattle:** SC ,IV

**Pigs:** IM

**Horses:** IV

**5. WITHDRAWAL PERIODS**

Withdrawal periods:

**Cattle:** meat and offal: 15 days; milk: 5 days.

**Pigs:** meat and offal: 5 days.

**Horses:** meat and offal: 5 days.

Not authorised to use in horses producing milk for human consumption.

**6. BATCH NUMBER**

Batch

**7. EXPIRY DATE**

EXP {month/year}

Once broached, use by...

**8. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**  
**Carton for 125 ml or 336 ml bottle**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 15 mg/ml oral suspension for horses  
meloxicam

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Meloxicam 15mg/ml

**3. PHARMACEUTICAL FORM**

Oral suspension

**4. PACKAGE SIZE**

125 ml  
336 ml

**5. TARGET SPECIES**

Horses

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Shake well before use.

To be administered either mixed with a small quantity of food, prior to feeding, or directly into the mouth.  
After administration, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period:

Meat and offal: 3 days

Not authorised for use in horses producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Do not use in pregnant or lactating mares.

**10. EXPIRY DATE**

EXP <{month/year}>

Once opened, use by:

Shelf-life after first opening the container: 6 months.

**11. SPECIAL STORAGE CONDITIONS****12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

EMDOKA bvba  
John Lijsenstraat 16  
B-2321 Hoogstraten  
Belgium

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/128/009 (125 ml)  
EU/2/11/128/010(336 ml)

**17. MANUFACTURER’S BATCH NUMBER**

Lot{number}



**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**  
**Label for bottles of 125 or 336 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 15 mg/ml oral suspension for horses  
meloxicam

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Meloxicam 15mg/ml

**3. PHARMACEUTICAL FORM**

Oral suspension

**4. PACKAGE SIZE**

125 ml  
336 ml

**5. TARGET SPECIES**

Horses

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Shake well before use.  
Read the package leaflet before use

**8. WITHDRAWAL PERIOD(S)**

Meat and offal: 3 days  
Not authorised for use in horses producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP <{month/year}>

Once opened, use by:

Shelf-life after first opening the container: 6 months.

<b>11. SPECIAL STORAGE CONDITIONS</b>
---------------------------------------

<b>12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY</b>
---

<b>13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable</b>
---

For animal treatment only. To be supplied only on veterinary prescription.

<b>14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”</b>
--

<b>15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b>
---

EMDOKA bvba  
John Lijsenstraat 16,  
B-2321 Hoogstraten  
Belgium

<b>16. MARKETING AUTHORISATION NUMBER(S)</b>
--

EU/2/11/128/009 (125 ml)

EU/2/11/128/010(336 ml)

<b>17. MANUFACTURER’S BATCH NUMBER</b>
--

Lot{number}

---

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE**  
**Carton for the 50 ml, 100 ml and 250 ml**  
**Label for 100 ml and 250 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 5 mg/ml solution for injection  
meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 5 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

50 ml  
100 ml  
250 ml

**5. TARGET SPECIES**

Cattle (calves and young cattle) and pigs

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Cattle: Single subcutaneous or intravenous injection.  
Pigs: Single intramuscular injection.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period:

**Cattle** (calves and young cattle): Meat and offal: 15 days

**Pigs:** Meat and offal: 5 days

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP (month/year)

Once broached, use by....

Shelf-life after first opening of the container: 28 days.

**11. SPECIAL STORAGE CONDITIONS**

Read the package leaflet before use.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Emdoka bvba  
John Lijzenstraat 16  
2321 Hoogstraten  
Belgium

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/128/004  
EU/2/11/128/005  
EU/2/11/128/006

**17. MANUFACTURER’S BATCH NUMBER**

Batch {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**  
**Label for 50 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 5 mg/ml solution for injection for cattle and pigs  
meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 5 mg/ml

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

50 ml

**4. ROUTE(S) OF ADMINISTRATION**

Cattle: SC, IV  
Pigs: IM

**5. WITHDRAWAL PERIOD(S)**

Withdrawal period:  
**Cattle** (calves and young cattle): Meat and offal: 15 days  
**Pigs:** Meat and offal: 5 days

**6. BATCH NUMBER**

Batch {number}

**7. EXPIRY DATE**

EXP (month/year)  
Once broached, use by ....

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE**  
**Carton for the 20 ml and 50 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 5 mg/ml solution for injection  
meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 5 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

20 ml  
50 ml

**5. TARGET SPECIES**

Dogs, cats

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Dogs: single intravenous or subcutaneous injection.  
Cats: single subcutaneous injection.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Not applicable.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP (month/year)  
Once broached, use by....  
Shelf-life after first opening of the container: 28 days.

**11. SPECIAL STORAGE CONDITIONS**

Read the package leaflet before use.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Emdoka bvba  
John Lijssenstraat 16  
2321 Hoogstraten  
Belgium

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/128/007  
EU/2/11/128/008

**17. MANUFACTURER’S BATCH NUMBER**

Batch {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**  
**Label for 20 ml and 50 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 5 mg/ml solution for injection for dogs and cats  
meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 5 mg/ml

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

20 ml  
50 ml

**4. ROUTE(S) OF ADMINISTRATION**

Dogs: IV or SC  
Cats: SC

**5. WITHDRAWAL PERIOD(S)**

Not applicable.

**6. BATCH NUMBER**

Batch {number}

**7. EXPIRY DATE**

EXP (month/year)  
Once broached, use by ....  
Shelf-life after first opening of the container: 28 days.

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.



## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET:

### Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

#### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

##### Marketing authorisation holder

Emdoka bvba  
J. Lijzenstraat 16  
B-2321 Hoogstraten  
Belgium

##### Manufacturer responsible for batch release:

Produlab Pharma bv  
NL-4941 SJ Raamsdonksveer  
The Netherlands

#### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Emdocam 20 mg/ml solution for injection for cattle, pigs and horses  
meloxicam

#### 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS

One ml contains:

##### **Active substance:**

Meloxicam 20 mg

##### **Excipient:**

Ethanol (96%) 150 mg

Clear yellow solution for injection.

#### 4. INDICATION(S)

##### Cattle

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

##### Pigs

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

##### Horses

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.

For the relief of pain associated with equine colic.

## **5. CONTRAINDICATIONS**

Do not use in horses less than 6 weeks of age.

Do not use in pregnant or lactating mares.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

## **6. ADVERSE REACTIONS**

A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.

In horses, a transient swelling at the injection site can occur but resolves without intervention.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

- The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Cattle, pigs and horses

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

### Cattle

Single subcutaneous or intravenous injection at a dose of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

### Pigs

Single intramuscular injection at a dose of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

### Horses

Single intravenous injection at a dose of 0.6 mg meloxicam/kg body weight (i.e. 3 ml/100 kg body

weight).

For use in the alleviation of inflammation and the relief of pain in both acute and chronic musculo-skeletal disorders, a suitable oral therapy containing meloxicam, administered in accordance with label recommendations, may be used for continuation of treatment.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Avoid introduction of contamination during use.

Do not broach the vial more than 50 times.

## **10. WITHDRAWAL PERIODS**

**Cattle:** meat and offal: 15 days; milk: 5 days

**Pigs:** meat and offal: 5 days

**Horses:** meat and offal: 5 days

Not authorised to use in horses producing milk for human consumption.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month.

Shelf-life after first opening the container: 28 days.

## **12. SPECIAL WARNING(S)**

Treatment of calves with Emdocam 20 minutes before dehorning reduces post-operative pain. Emdocam alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

### Special precautions for use in animals:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

### Pregnancy and lactation

Cattle and pigs: Can be used during pregnancy and lactation.

Horses: Do not use in pregnant and lactating mares.

### Interactions with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.

Overdose (symptoms, emergency procedures, antidotes):

In case of overdose, symptomatic treatment should be initiated.

Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Any unused medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

**15. OTHER INFORMATION**

Pack size of 1 colourless Type I glass vial containing 50 ml, 100 ml or 250 ml. Each vial is closed with a bromobutyl rubber stopper and sealed with an aluminium cap.  
Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Lietuva**

OÜ Zoovetvaru  
Uusaru 5  
EE-Saue 76505  
Tel: +372 6 709 006

**Република България**

БИОСФЕРА ФАРМ ЕООД  
ул.Юрий Гагарин № 50  
BG гр. Костинброд 2230  
Тел: + 359 885917017

**Luxembourg/Luxemburg**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Česká republika**

BIOPHARM, Výzkumný ústav biofarmacie  
a veterinárních léčiv, a.s  
Pohoří – Chotouň 90  
CZ-254 49 Jilové u Prahy  
Tel: +420 241 950 383

**Magyarország**

Meditrix Kft.  
Ady E. u. 5  
H-7020 Dunaföldvár  
Tel.: +36 75 542 940

**Danmark**

ChemVet dk A/S  
A.C. Illums Vej 6  
DK-8600 Silkeborg  
Tlf: +45 8681 7522

**Deutschland**

WDT eG  
Siemensstr. 14  
D-30827 Garbsen  
Tel: +49 5131 705 0

**Eesti**

OÜ Zoovetvaru  
Uusaru 5  
EE-Saue 76505  
Tel: +372 6 709 006

**Ελλάδα**

FATRO-HELLAS SPLTD  
2ο χλμ. ΠΑΙΑΝΙΑΣ-ΣΠΑΤΩΝ  
GR-190 02 ΠΑΙΑΝΙΑ  
Τηλ: + 30 210 6644331

**España**

Divasa-Farmavic S.A.  
Ctra. Sant Hipòlit, km 71  
E-08503 Gurb-Vic  
Tel: +34 93 886 01 00

**France**

Axience SAS  
Tour Eссор - 14, rue Scandicci  
F-93500 Pantin  
Tél. +33 1 41 83 23 17

**Hrvatska**

Vet Consulting d.o.o.  
Matije Gupca 42  
43500 Daruvar  
Tel: +385 43 440 527

**Ireland**

Duggan Veterinary Supplies Ltd.,  
Holycross,  
Thurles,  
Co Tipperary  
Ireland  
Tel: +353 (0) 504 43169

**Ísland**

Emdoka bvba

**Malta**

Emdoka bvba  
John Lijssenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Nederland**

Emdoka bvba  
John Lijssenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Norge**

Emdoka bvba  
John Lijssenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Österreich**

Richter Pharma AG  
Feldgasse 19, A  
A-4600 Wels  
Tel: +43 7242 490 0

**Polska**

Fatro Polska Sp. z o.o.  
ul. Bolońska 1  
PL-55 040 Kobierzyce  
Tel.: +48 71 311 11 11

**Portugal**

Divasa Farmavic de Portugal, Produtos e  
Equipamentos Veterinários, Lda.  
Praceta Jaime Cortesão  
Nº 1 – R/C Loja Esq.  
2625-170 Póvoa de Santa Iria  
Tel: +351 219 739 130

**România**

SC Altius SRL  
Str Iancu Capitanu nr 38 Ap 1  
Sector 2, Bucuresti – RO  
Tel: + 40 021 310 88 80

**Slovenija**

TPR d.o.o.  
Litostrojska cesta 44e,  
1000 Ljubljana  
Slovenia  
Tel: +386 (0)1 505 5882

**Slovenská republika**

Emdoka bvba

John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Italia**

Azienda Terapeutica Italiana A.T.I. s.r.l.  
Via Emilia 285  
I-40064 Ozzano dell'Emilia – Bologna  
Tel: +39 051 6512711

**Κύπρος**

Σπύρος Σταυρινίδης Κέμικαλς Λτδ  
Λεωφ. Στασίνου 28,  
1060 Λευκωσία, Κύπρος  
Τηλ: +357 22 447464

**Latvija**

OÜ Zoovetvaru  
Uusaru 5  
EE-Saue 76505  
Tel: +372 6 709 006

John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Suomi/Finland**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Sverige**

ChemVet dk A/S  
A.C. Illums Vej 6  
DK-8600 Silkeborg  
Tel: +45 8681 7522

**United Kingdom (Northern Ireland)**

Duggan Veterinary Supplies Ltd.,  
Holycross,  
Thurles,  
Co Tipperary  
Ireland  
Tel: +353 (0) 504 43169

**PACKAGE LEAFLET:**  
**Emdocam 15 mg/ml oral suspension for horses**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE:**

Marketing Authorisation Holder:

Emdoka bvba  
John Lijsenstraat 16  
B-2321 Hoogstraten  
Belgium.

Manufacturer responsible for batch release:

Produlab Pharma bv  
NL-4941 SJ Raamsdonksveer  
The Netherlands.

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT:**

Emdocam 15 mg/ml oral suspension for horses  
Meloxicam

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S):**

Each ml contains:

**Active substance:**

Meloxicam	15.0 mg
-----------	---------

**Excipients:**

Sodium benzoate	1.5 mg
-----------------	--------

Yellow suspension.

**4. INDICATIONS:**

Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.

**5. CONTRA-INDICATIONS:**

Do not use in pregnant or lactating mares.

Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in horses less than 6 weeks of age.

**6. ADVERSE REACTIONS:**



Isolated cases of adverse reactions typically associated with NSAIDs were observed in clinical trials (slight urticaria, diarrhoea). Symptoms were reversible.

Loss of appetite, lethargy, abdominal pain and colitis have been reported in very rare cases.

Anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically in very rare cases.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

Very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)

Common (more than 1 but less than 10 animals in 100 animals)

Uncommon (more than 1 but less than 10 animals in 1,000 animals)

Rare (more than 1 but less than 10 animals in 10,000 animals)

Very rare (less than 1 animals in 10,000 animals, including isolated reports)

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicines has not worked, please inform your veterinary surgeon.

## **7. TARGET SPECIES:**

Horses.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION:**

### Dosage

Oral suspension to be administered at a dosage of 0.6 mg/kg body weight, once daily, up to 14 days.

### Method and route of administration

Shake well before use. To be administered either mixed with a small quantity of food, prior to feeding, or directly into the mouth.

The suspension should be given using the measuring syringe provided in the package. The syringe fits onto the bottle and has volume scale and a “kg-body weight” scale which corresponds to the maintenance dose (i.e. 0.6 mg meloxicam / kg body weight).

After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

## **9. ADVICE ON CORRECT ADMINISTRATION:**

Avoid introduction of contamination during use.

## **10. WITHDRAWAL PERIODS:**

Meat and offal: 3 days

Not authorised for use in horses producing milk for human consumption.

## **11. SPECIAL STORAGE PRECAUTIONS:**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and bottle after “EXP”.

Shelf-life after first opening the container: 6 months.

## **12. SPECIAL WARNINGS:**

### Special precautions for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of renal toxicity.

### Special precautions to be taken by the person administering the product

People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

### Pregnancy, lactation or lay

See section “Contraindications”.

### Interactions with other medicinal products and other forms of interaction

Do not administer concurrently with glucocorticoids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.

### Overdose (symptoms, emergency procedures, antidotes)

In the case of overdosage, symptomatic treatment should be initiated.

### Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY:**

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

## **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED:**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

## 15. OTHER INFORMATION:

### Pack sizes:

Cardboard box with 1 bottle of 125 ml and a measuring syringe

Cardboard box with 1 bottle of 336 ml and a measuring syringe

Not all pack sizes may be marketed.

### **België/Belgique/Belgien**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

### **Lietuva**

OÜ Zoovetvaru  
Uusaru 5  
EE-Saue 76505  
Tel: +372 6 709 006

### **Република България**

БИОСФЕРА ФАРМ ЕООД  
ул.Юрий Гагарин № 50  
BG гр. Костинброд 2230  
Тел: + 359 885917017

### **Luxembourg/Luxemburg**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

### **Česká republika**

BIOPHARM, Výzkumný ústav biofarmacie  
a veterinárních léčiv, a.s  
Pohoří – Chotouň 90  
CZ-254 49 Jilové u Prahy  
Tel: +420 241 950 383

### **Magyarország**

Meditrix Kft.  
Ady E. u. 5  
H-7020 Dunaföldvár  
Tel.: +36 75 542 940

### **Danmark**

ChemVet dk A/S  
A.C. Illums Vej 6  
DK-8600 Silkeborg  
Tlf: +45 8681 7522

### **Malta**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

### **Deutschland**

WDT eG  
Siemensstr. 14  
D-30827 Garbsen  
Tel: +49 5131 705 0

### **Nederland**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

### **Eesti**

OÜ Zoovetvaru  
Uusaru 5  
EE-Saue 76505  
Tel: +372 6 709 006

### **Norge**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

### **Ελλάδα**

FATRO-HELLAS SPLTD  
2ο χλ. ΠΑΙΑΝΙΑΣ-ΣΠΑΤΩΝ  
GR-190 02 ΠΑΙΑΝΙΑ  
Τηλ: + 30 210 6644331

### **Österreich**

Richter Pharma AG  
Feldgasse 19, A  
A-4600 Wels  
Tel: +43 7242 490 0

### **España**

Divasa-Farmavic S.A.

### **Polska**

Fatro Polska Sp. z o.o.

Ctra. Sant Hipòlit, km 71  
E-08503 Gurb-Vic  
Tel: +34 93 886 01 00

**France**

Axience SAS  
Tour Eссор - 14, rue Scandicci  
F-93500 Pantin  
Tél. +33 1 41 83 23 17

**Hrvatska**

Vet Consulting d.o.o.  
Matije Gupca 42  
43500 Daruvar  
Tel: +385 43 440 527

**Ireland**

Duggan Veterinary Supplies Ltd.,  
Holycross,  
Thurles,  
Co Tipperary  
Ireland  
Tel: +353 (0) 504 43169

**Ísland**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Italia**

Azienda Terapeutica Italiana A.T.I. s.r.l.  
Via Emilia 285  
I-40064 Ozzano dell'Emilia – Bologna  
Tel: +39 051 6512711

**Κύπρος**

Σπύρος Σταυρινίδης Κέμικαλς Λτδ  
Λεωφ. Στασίνου 28,  
1060 Λευκωσία, Κύπρος  
Τηλ: +357 22 447464

**Latvija**

OÜ Zoovetvaru  
Uusaru 5  
EE-Saue 76505  
Tel: +372 6 709 006

ul. Bolońska 1  
PL-55 040 Kobierzyce  
Tel.: +48 71 311 11 11

**Portugal**

Divasa Farmavic de Portugal, Produtos e  
Equipamentos Veterinários, Lda.  
Praceta Jaime Corteção  
Nº 1 – R/C Loja Esq.  
2625-170 Póvoa de Santa Iria  
Tel: +351 219 739 130

**România**

SC Altius SRL  
Str Iancu Capitanu nr 38 Ap 1  
Sector 2, Bucuresti – RO  
Tel: + 40 021 310 88 80

**Slovenija**

TPR d.o.o.  
Litostrojska cesta 44e,  
1000 Ljubljana  
Slovenia  
Tel: +386 (0)1 505 5882

**Slovenská republika**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Suomi/Finland**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Sverige**

ChemVet dk A/S  
A.C. Illums Vej 6  
DK-8600 Silkeborg  
Tel: +45 8681 7522

**United Kingdom (Northern Ireland)**

Duggan Veterinary Supplies Ltd.,  
Holycross,  
Thurles,  
Co Tipperary  
Ireland  
Tel: +353 (0) 504 43169

**PACKAGE LEAFLET:**  
**Emdocam 5 mg/ml solution for injection for cattle and pigs**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

Emdoka bvba  
John Lijsenstraat 16  
2321 Hoogstraten  
Belgium

Manufacturer responsible for the batch release:

Produlab Pharma B.V.  
Forellenweg 16  
4941 SJ Raamsdonksveer  
The Netherlands

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 5 mg/ml solution for injection for cattle and pigs  
meloxicam

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS**

Each ml contains:

**Active substance:**

Meloxicam 5 mg

**Excipients:**

Ethanol 150 mg

Clear yellow solution for injection.

**4. INDICATION(S)**

Cattle (calves and young cattle):

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For the relief of post-operative pain following dehorning in calves.

Pigs:

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For the relief of post-operative pain associated with minor soft tissue surgery such as castration.

**5. CONTRAINDICATIONS**

**Cattle:**

Do not use in cattle suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

**Pigs:**

Do not use in pigs suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in pigs less than 2 days old.

**6. ADVERSE REACTIONS**

Subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.

Anaphylactic reactions, which may be serious (including fatal), may occur in very rare cases and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

**7. TARGET SPECIES**

Cattle (calves and young cattle) and pigs

**8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION****Cattle:**

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

**Pigs:**Locomotor disorders:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2 ml/25 kg body weight). If required, a second administration of meloxicam can be given after 24 hours.

Reduction of post-operative pain:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 0.4 ml/5 kg body weight) before surgery.

Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of body weight.

As the vial should not be broached more than 50 times the user should select the most appropriate vial size according to the target species to be treated.

**9. ADVICE ON CORRECT ADMINISTRATION**

Avoid introduction of contamination during use.

Do not breach the vial more than 50 times.

## **10. WITHDRAWAL PERIOD(S)**

**Cattle** (calves and young cattle): meat and offal: 15 days

**Pigs:** meat and offal: 5 days

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.

Shelf-life after first opening the container: 28 days.

## **12. SPECIAL WARNING(S)**

Special warnings for each target species:

### **Cattle:**

Treatment of calves with Emdocam 20 minutes before dehorning reduces post-operative pain.

Emdocam alone will not provide adequate pain relief during the dehorning procedure.

To obtain pain relief during surgery co-medication with an appropriate anaesthetic/sedative/analgesic is needed.

To obtain the best possible pain-relieving effect post-surgery Emdocam should be administered 30 minutes before surgical intervention.

### **Pigs:**

Treatment of piglets with Emdocam before castration reduces post-operative pain.

To obtain pain relief during surgery co-medication with an appropriate anaesthetic/sedative/analgesic is needed.

To obtain the best possible pain-relieving effect post-surgery Emdocam should be administered 30 minutes before surgical intervention.

Special precautions for use in animals:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in any dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

During anaesthesia, monitoring and fluid therapy should be considered as standard practice.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Meloxicam may cause allergic reactions. People with known hypersensitivity to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

Accidental self-injection may give rise to pain. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

Pregnancy and lactation:

**Cattle:** Can be used during pregnancy.

**Pigs:** Can be used during pregnancy and lactation.

Interactions with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.

Overdose (symptoms, emergency procedures, antidotes):

In case of overdose symptomatic treatment should be initiated.

Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

**15. OTHER INFORMATION**

Pack sizes:

Cardboard box containing 1 vial of 50 ml

Cardboard box containing 1 vial of 100 ml

Cardboard box containing 1 vial of 250 ml

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**

Emdoka bvba

John Lijsenstraat 16

BE-2321 Hoogstraten

Tel : +32 3 315 04 26

**Lietuva**

OÜ Zoovetvaru

Uusaru 5

EE-Saue 76505

Tel: +372 6 709 006

**Република България**

БИОСФЕРА ФАРМ ЕООД

ул.Юрий Гагарин № 50

BG гр. Костинброд 2230

Тел: + 359 885917017

**Luxembourg/Luxemburg**

Emdoka bvba

John Lijsenstraat 16

BE-2321 Hoogstraten

Tel : +32 3 315 04 26

**Česká republika**

BIOPHARM, Výzkumný ústav biofarmacie

**Magyarország**

Meditrix Kft.



a veterinárních léčiv, a.s  
Pohoří – Chotouň 90  
CZ-254 49 Jilové u Prahy  
Tel: +420 241 950 383

#### **Danmark**

ChemVet dk A/S  
A.C. Illums Vej 6  
DK-8600 Silkeborg  
Tlf: +45 8681 7522

#### **Deutschland**

WDT eG  
Siemensstr. 14  
D-30827 Garbsen  
Tel: +49 5131 705 0

#### **Eesti**

OÜ Zoovetvaru  
Uusaru 5  
EE-Saue 76505  
Tel: +372 6 709 006

#### **Ελλάδα**

FATRO-HELLAS SPLTD  
2ο χιλ. ΠΑΙΑΝΙΑΣ-ΣΠΑΤΩΝ  
GR-190 02 ΠΑΙΑΝΙΑ  
Τηλ: + 30 210 6644331

#### **España**

Divasa-Farmavic S.A.  
Ctra. Sant Hipòlit, km 71  
E-08503 Gurb-Vic  
Tel: +34 93 886 01 00

#### **France**

Axience SAS  
Tour Essor - 14, rue Scandicci  
F-93500 Pantin  
Tél. +33 1 41 83 23 17

#### **Hrvatska**

Vet Consulting d.o.o.  
Matije Gupca 42  
43500 Daruvar  
Tel: +385 43 440 527

#### **Ireland**

Duggan Veterinary Supplies Ltd.,  
Holycross,  
Thurles,  
Co Tipperary  
Ireland

Ady E. u. 5  
H-7020 Dunaföldvár  
Tel.: +36 75 542 940

#### **Malta**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

#### **Nederland**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

#### **Norge**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

#### **Österreich**

Richter Pharma AG  
Feldgasse 19, A  
A-4600 Wels  
Tel: +43 7242 490 0

#### **Polska**

Fatro Polska Sp. z o.o.  
ul. Bolońska 1  
PL-55 040 Kobierzyce  
Tel.: +48 71 311 11 11

#### **Portugal**

Divasa Farmavic de Portugal, Produtos e  
Equipamentos Veterinários, Lda.  
Praceta Jaime Cortesão  
Nº 1 – R/C Loja Esq.  
2625-170 Povoia de Santa Iria  
Tel: +351 219 739 130

#### **România**

SC Altius SRL  
Str Iancu Capitanu nr 38 Ap 1  
Sector 2, Bucuresti – RO  
Tel: + 40 021 310 88 80

#### **Slovenija**

TPR d.o.o.  
Litostrojska cesta 44e,  
1000 Ljubljana  
Slovenia  
Tel: +386 (0)1 505 5882

Tel: +353 (0) 504 43169

**Ísland**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Italia**

Azienda Terapeutica Italiana A.T.I. s.r.l.  
Via Emilia 285  
I-40064 Ozzano dell'Emilia – Bologna  
Tel: +39 051 6512711

**Κύπρος**

Σπύρος Σταυρινίδης Κέμικαλς Λτδ  
Λεωφ. Στασίνου 28,  
1060 Λευκωσία, Κύπρος  
Τηλ: +357 22 447464

**Latvija**

OÜ Zoovetvaru  
Uusaru 5  
EE-Saue 76505  
Tel: +372 6 709 006

**Slovenská republika**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Suomi/Finland**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Sverige**

ChemVet dk A/S  
A.C. Illums Vej 6  
DK-8600 Silkeborg  
Tel: +45 8681 7522

**United Kingdom (Northern Ireland)**

Duggan Veterinary Supplies Ltd.,  
Holycross,  
Thurles,  
Co Tipperary  
Ireland  
Tel: +353 (0) 504 43169

**PACKAGE LEAFLET:**  
**Emdocam 5 mg/ml solution for injection for dogs and cats**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

Emdoka bvba  
John Lijsenstraat 16  
2321 Hoogstraten  
Belgium

Manufacturer responsible for the batch release:

Produlab Pharma B.V.  
Forellenweg 16  
4941 SJ Raamsdonksveer The Netherlands

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Emdocam 5 mg/ml solution for injection for dogs and cats  
meloxicam

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS**

Each ml contains:

**Active substance:**

Meloxicam      5 mg

**Excipients:**

Ethanol      150 mg

Clear yellow solution for injection.

**4. INDICATION(S)**

Dogs:

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

Cats:

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

**5. CONTRAINDICATIONS**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in pregnant or lactating dogs and cats.

Do not use in dogs and cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in dog and cats less than 6 weeks of age nor in cats of less than 2 kg.

## **6. ADVERSE REACTIONS**

Typical adverse reactions of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have rarely been reported.

Elevated liver enzymes have been reported in very rare cases.

Haemorrhagic diarrhoea, haematemesis and gastrointestinal ulceration have been reported in very rare cases. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. Anaphylactoid reactions may occur in very rare cases and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Dogs, cats

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

### **Dogs:**

#### Musculo-skeletal disorders:

Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight).

#### Reduction of post-operative pain (over a period of 24 hours):

Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight) before surgery, for example at the time of induction of anaesthesia.

### **Cats:**

#### Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery:

Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia.

As the vial should not be broached more than 50 times the user should select the most appropriate vial size according to the target species to be treated.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Avoid introduction of contamination during use.

## **10. WITHDRAWAL PERIOD(S)**

Not applicable.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.

Shelf-life after first opening the container: 28 days.

## **12. SPECIAL WARNING(S)**

Special warnings for each target species:

None.

Special precautions for use in animals:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in any dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

During anaesthesia, monitoring and fluid therapy should be considered as standard practice. Any oral follow-up therapy using meloxicam or other NSAIDs should not be administered in cats, as appropriate dosage regimens for such follow-up treatments have not been established.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Meloxicam may cause allergic reactions. People with known hypersensitivity to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

Accidental self-injection may give rise to pain. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

Pregnancy and lactation:

Do not use in pregnant or lactating dogs or cats.

Interactions with other medicinal products and other forms of interaction:

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Emdocam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

Overdose (symptoms, emergency procedures, antidotes):

In case of overdose symptomatic treatment should be initiated.

Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

**15. OTHER INFORMATION**

Pack sizes:

Cardboard box containing 1 vial of 20 ml

Cardboard box containing 1 vial of 50 ml

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Lietuva**

OÜ Zoovetvaru  
Uusaru 5  
EE-Saue 76505  
Tel: +372 6 709 006

**Република България**

БИОСФЕРА ФАРМ ЕООД  
ул.Юрий Гагарин № 50  
BG гр. Костинброд 2230  
Тел: + 359 885917017

**Luxembourg/Luxemburg**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Česká republika**

BIOPHARM, Výzkumný ústav biofarmacie  
a veterinárních léčiv, a.s  
Pohoří – Chotouň 90  
CZ-254 49 Jílové u Prahy  
Tel: +420 241 950 383

**Magyarország**

Meditrix Kft.  
Ady E. u. 5  
H-7020 Dunaföldvár  
Tel.: +36 75 542 940

**Danmark**

ChemVet dk A/S  
A.C. Illums Vej 6  
DK-8600 Silkeborg  
Tlf: +45 8681 7522

**Malta**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Deutschland**

WDT eG  
Siemensstr. 14  
D-30827 Garbsen

**Nederland**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten

Tel: +49 5131 705 0

**Eesti**

OÜ Zoovetvaru  
Uusaru 5  
EE-Saue 76505  
Tel: +372 6 709 006

**Ελλάδα**

FATRO-HELLAS SPLTD  
2ο χλμ. ΠΑΙΑΝΙΑΣ-ΣΠΑΤΩΝ  
GR-190 02 ΠΑΙΑΝΙΑ  
Τηλ: + 30 210 6644331

**España**

Divasa-Farmavic S.A.  
Ctra. Sant Hipòlit, km 71  
E-08503 Gurb-Vic  
Tel: +34 93 886 01 00

**France**

Axience SAS  
Tour Eссор - 14, rue Scandicci  
F-93500 Pantin  
Tél. +33 1 41 83 23 17

**Hrvatska**

Vet Consulting d.o.o.  
Matije Gupca 42  
43500 Daruvar  
Tel: +385 43 440 527

**Ireland**

Duggan Veterinary Supplies Ltd.,  
Holycross,  
Thurles,  
Co Tipperary  
Ireland  
Tel: +353 (0) 504 43169

**Ísland**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Italia**

Azienda Terapeutica Italiana A.T.I. s.r.l.  
Via Emilia 285  
I-40064 Ozzano dell'Emilia – Bologna  
Tel: +39 051 6512711

**Κύπρος**

Tel : +32 3 315 04 26

**Norge**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Österreich**

Richter Pharma AG  
Feldgasse 19, A  
A-4600 Wels  
Tel: +43 7242 490 0

**Polska**

Fatro Polska Sp. z o.o.  
ul. Bolońska 1  
PL-55 040 Kobierzyce  
Tel.: +48 71 311 11 11

**Portugal**

Divasa Farmavic de Portugal, Produtos e  
Equipamentos Veterinários, Lda.  
Praceta Jaime Corteção  
Nº 1 – R/C Loja Esq.  
2625-170 Póvoa de Santa Iria  
Tel: +351 219 739 130

**România**

SC Altius SRL  
Str Iancu Capitanu nr 38 Ap 1  
Sector 2, Bucuresti – RO  
Tel: + 40 021 310 88 80

**Slovenija**

TPR d.o.o.  
Litostrojska cesta 44e,  
1000 Ljubljana  
Slovenia  
Tel: +386 (0)1 505 5882

**Slovenská republika**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Suomi/Finland**

Emdoka bvba  
John Lijsenstraat 16  
BE-2321 Hoogstraten  
Tel : +32 3 315 04 26

**Sverige**

Σπύρος Σταυρινίδης Κέμικαλς Ατδ  
Λεωφ. Στασίνου 28,  
1060 Λευκωσία, Κύπρος  
Τηλ: +357 22 447464

**Latvija**  
OÜ Zoovetvaru  
Uusaru 5  
EE-Saue 76505  
Tel: +372 6 709 006

ChemVet dk A/S  
A.C. Illums Vej 6  
DK-8600 Silkeborg  
Tel: +45 8681 7522

**United Kingdom (Northern Ireland)**  
Duggan Veterinary Supplies Ltd.,  
Holycross,  
Thurles,  
Co Tipperary  
Ireland  
Tel: +353 (0) 504 43169